

Discussant Paper 250

Screening, Staging, Epidemiology

Paul Baas

Thoracic Oncology

ELCC, ESMO, IASLC

Friday March 28, 2014

26-29 March 2014, Geneva, Switzerland

Organisers



International As

NETHERLANDS
CANCER
INSTITUTE



ANTONI VAN LEEUWENHOEK

JP van Meerbeeck (250)

International comparison of treatment and survival for pleural mesothelioma, combined analysis of 9.104 patients from Belgium, The Netherlands and England

26-29 March 2014, Geneva, Switzerland

Organisers



Presentation

- MPM is refractory to treatment
- Differences in care and treatment exist
- Novel chemotherapy treatment can effect outcome
- 3 countries were examined in the period 2007-2011:
Belgium 900 cases in 3 years;
Netherlands 2.306 cases in 4 years
United Kingdom 5.808 in 4 years

Results


	Belgium	Netherlands	United Kingdom
Age > 70 years		59%	
Male gender		84%	
Chemotherapy	53%	41%	37%
OS (months)	10.6	9.5	9.2
Cases	900	2306	5808
Population (2008-10) in Millions	10.9	16.7	61.8

26-29 March 2014, Geneva, Switzerland

Organisers


Results

- More CT in Belgium
- More RT in the UK
- More surgery in Belgium




Median survival by country, age-group and treatment with chemotherapy

Without chemotherapy



With chemotherapy



26-29 March 2014, Geneva, Switzerland

Organisers

Discussion

	PRO	CON
Study set-up	Observational study 3 countries	Selected countries
Relevance	informative	Practice change?
# of cases/year (cancer registry)	Representative and complete	Belgium 300 Netherlands 450 United Kingdom 2500
Treatment eagerness??	Belgium	Netherlands
Survival	Same when corrected for CT and age	No improvement

Conclusion and Needs

- Good introspection; have to examine other countries
- Treatment differences exist but do they effect outcome?
- Must have been easy to do for a:

